Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635212 | 0.85 | CYP3A4 (0.44) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4000406 | 0.85 | CYP3A4 (0.44) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL20873230 | 0.85 | TDP1 (0.44) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL28294523 | 0.81 | CYP3A4 (0.41) | CYP3A4TDP1MYCESR2TSHR | |
| SCHEMBL21331888 | 0.81 | CYP3A4 (0.44) | CYP3A4TDP1MYCESR1ESR2 | |
| SCHEMBL1011883 | 0.80 | TDP1 (0.52) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL1120987 | 0.80 | CYP3A4 (0.58) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL1768305 | 0.80 | MYC (0.41) | DRD1CYP3A4TDP1MYCESR1 | |
| SCHEMBL31059891 | 0.78 | CYP3A4 (0.55) | DRD1CYP3A4TDP1ESR1ESR2 | |
| Water SCHEMBL1131752 | 0.78 | CYP3A4 (0.55) | DRD1CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124805-B2 | Allyl acetate hydroformylation process | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110124904-A1 | Allyl acetate hydroformylation process | LYONDELL CHEMICAL TECHNOLOGY, L.P. | 2011-05-26 | — | — | US | disclosed |
| US-7655821-B1 | Direct hydrocarbonylation process | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009123675-A1 | IMPROVED CARBONYLATION PROCESS | EASTMAN CHEMICAL COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247783-A1 | CARBONYLATION PROCESS | EASTMAN CHEMICAL COMPANY (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0915839-B1 | MANUFACTURING PROCESS FOR 6-AMINOCAPRONITRILE | BASF AG (DE) | 2001-09-19 | — | — | EP | disclosed |
| US-6048997-A | CARBONYLATION AND HYDROGENATION, DECARBONYLATION TO FORM HYDROFORMYLATION AND REMOVAL OF 5-FORMYLVALERONITRILE, HYDROGENATION AND ISOLATION 6-AMINOCAPRONITRILE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247783-A1 | CARBONYLATION PROCESS | CA4, HAO2, CA9 | DRD1 644/4885CYP3A4 171/4885TDP1 4379/4885 |
| US-20110124904-A1 | Allyl acetate hydroformylation process | GNPAT, DHPS, ALDH3A1 | DRD1 2526/4885CYP3A4 317/4885TDP1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.